Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients

British Journal of Cancer

Volumn 91, Issue 2, 2004, Pages 287-296

  Yao, A ^a   Harada, M ^a   Matsueda, S ^a   Ishihara, Y ^a   Shomura, H ^a   Noguchi, M ^a   Matsuoka, K ^a   Hara, I ^b   Kamidono, S ^b   Itoh, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; HLA A24; Parathyroid hormone related protein (PTHrP); Peptide; Prostate cancer

Indexed keywords

CD8 ANTIGEN; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; PARATHYROID HORMONE RELATED PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

EID: 3843086260     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601960     Document Type: Article

References (37)

1. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 81: 267-268
2. Francini G, Scardino A, Kosmatopoulos K, Lemonnier F, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi GM, Correale P (2002) High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 169: 4840-4844
3. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000. CA Cancer J Clin 50: 7-33
4. Guise TA (1997) Parathyroid hormone-related protein and bone metastases. Cancer 80: 1572-1580
5. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Hamilton MJ (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53: 109-117
6. + T cells reactive to a class I tumor peptide. J Immunol 172: 2659-2667
7. + prostate cancer patients. Prostate 57: 152-159
8. Harada M, Noguchi M, Itoh K (2003b) Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncl 8: 193-199
9. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A new culture protocol to detect peptide-specific cytotixic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228
10. Imanishi T, Akazawa T, Kimura A (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA 1991, Tsuji K, Aizawa M, Sasazuki T (eds). Vol. 1, pp 1065-1220. Oxford: Oxford Scientific Publications
11. Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakasugi H (2001) Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 166: 1508-1513
12. Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF, Hock J, Potts JT, Kronenberg HM, Serge GV (1991) AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related protein. Science 254: 1024-1026
13. + prostate cancer patients. Cancer Sci 94: 622-627
14. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, J Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219-230
15. + patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 53: 479-489
16. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94: 548-556
17. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Katagiri K, Rikimaru H, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamda A, Todo S, Itoh K, Yamana H (2004) Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937
18. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29: 371-380
19. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL (1999) Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 73-78
20. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K (2002) Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32: 826-836
21. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332
22. Noguchi M, Mine T, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80-92
23. Ohkouchi S, Yamada A, Imai N, Mine T, Harada K, Shichijo S, Maeda Y, Saijyo Y, Nukiwa T, Itoh K (2002) Non-mutated tumor rejection antigen peptides elicit type-1 allergy in the majority of healthy individuals. Tissue Antigens 59: 259-272
24. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-175
25. Philbrick WM, Wysolmerski JJ, Galbarith S, Holt E, Orloff J, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF (1996) Defining the roles of parathyroid hormone related protein in normal physiology. Physiol Rev 76: 127-173
26. Rammensee HG, Friege T, Stevanovics S (1995) MHC ligands and peptides motifs. Immunogenetics 41: 178-228
27. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15
28. Rosenberg SA (1999) A new era for cancer immunotheraphy based on the genes that encode cancer antigens. Immunity 10: 281-287
29. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Prkhurst MA, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327
30. 2+-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab 281: 1267-1274
31. Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immunogical evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808
32. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valon FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903
33. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ, Martin TJ, Wood WI (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893-896
34. Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T (2003) Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery. J Immunother 26: 357-366
35. Tian J, Smogorzewski M, Kedes L, Massry SG (1993) Parathyroid hormone-parathyroid hormone-related protein receptor messenger RNA is present in many tissues besides the kidney. Am J Nephrol 13: 210-213
36. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 39-44
37. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T (2004) Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 27: 60-72